Related references
Note: Only part of the references are listed.Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink
Naveed Sattar et al.
CIRCULATION (2018)
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension
Robert Chilton et al.
DIABETES OBESITY & METABOLISM (2017)
Barriers to Clinical Research Participation Among African Americans
Rebecca Luebbert et al.
JOURNAL OF TRANSCULTURAL NURSING (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Factors influencing enrollment of African Americans in the Look AHEAD trial
David L. Mount et al.
CLINICAL TRIALS (2012)
The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy
Thomas D. Giles et al.
BLOOD PRESSURE MONITORING (2011)
Blood Pressure Control in Diabetes Temporal progress yet persistent racial disparities: national results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study
Doyle M. Cummings et al.
DIABETES CARE (2010)